News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
PEEK brings a new quality to dental care for patients
OVAPEX is a unique formula developed by the team of scientists and doctors at Green Milk Concepts
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Subscribe To Our Newsletter & Stay Updated
